RU2011139180A - Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции - Google Patents
Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции Download PDFInfo
- Publication number
- RU2011139180A RU2011139180A RU2011139180/15A RU2011139180A RU2011139180A RU 2011139180 A RU2011139180 A RU 2011139180A RU 2011139180/15 A RU2011139180/15 A RU 2011139180/15A RU 2011139180 A RU2011139180 A RU 2011139180A RU 2011139180 A RU2011139180 A RU 2011139180A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- composition
- ifn
- Prior art date
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims 7
- 230000003908 liver function Effects 0.000 title claims 7
- 239000003112 inhibitor Substances 0.000 title claims 6
- 239000002777 nucleoside Substances 0.000 title claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims 3
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 87
- 239000000203 mixture Substances 0.000 claims abstract 44
- 150000003839 salts Chemical class 0.000 claims abstract 41
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 15
- 102000006992 Interferon-alpha Human genes 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 12
- 102000014150 Interferons Human genes 0.000 claims 11
- 108010050904 Interferons Proteins 0.000 claims 11
- 229940079322 interferon Drugs 0.000 claims 11
- 108010010648 interferon alfacon-1 Proteins 0.000 claims 11
- 108010074328 Interferon-gamma Proteins 0.000 claims 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 8
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 8
- 229960000329 ribavirin Drugs 0.000 claims 8
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 8
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 6
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 6
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 6
- 230000001771 impaired effect Effects 0.000 claims 6
- 229920001427 mPEG Polymers 0.000 claims 6
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 6
- 102100037850 Interferon gamma Human genes 0.000 claims 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 5
- 101800001530 Thymosin alpha Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 5
- 229960003073 pirfenidone Drugs 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims 4
- UJQBOUAGWGVOTI-XSSZXYGBSA-N 1-[(2r,4s,5r)-4-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@](O)(N=[N+]=[N-])C1 UJQBOUAGWGVOTI-XSSZXYGBSA-N 0.000 claims 3
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 3
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 3
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 3
- 108010008165 Etanercept Proteins 0.000 claims 3
- 229940121759 Helicase inhibitor Drugs 0.000 claims 3
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 claims 3
- 102000008070 Interferon-gamma Human genes 0.000 claims 3
- 108060004795 Methyltransferase Proteins 0.000 claims 3
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 3
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 claims 3
- 229960004748 abacavir Drugs 0.000 claims 3
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 3
- 229960002964 adalimumab Drugs 0.000 claims 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical group N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 3
- 229960000724 cidofovir Drugs 0.000 claims 3
- 229940014461 combivir Drugs 0.000 claims 3
- 229960000403 etanercept Drugs 0.000 claims 3
- 229940090438 infergen Drugs 0.000 claims 3
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 3
- 229960003130 interferon gamma Drugs 0.000 claims 3
- 229950003954 isatoribine Drugs 0.000 claims 3
- 229940127073 nucleoside analogue Drugs 0.000 claims 3
- 229960000311 ritonavir Drugs 0.000 claims 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 3
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 3
- 229950006081 taribavirin Drugs 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- TUYVLHMUEJTDNN-WVAUJHLCSA-N CCC[C@@H](C(C(NC1CC1)=O)=O)NC([C@H](CCC1)N1C([C@H](C(C)(C)C)NC([C@H](C1CCCCC1)NC(c1nccnc1)=O)=O)=O)=O Chemical compound CCC[C@@H](C(C(NC1CC1)=O)=O)NC([C@H](CCC1)N1C([C@H](C(C)(C)C)NC([C@H](C1CCCCC1)NC(c1nccnc1)=O)=O)=O)=O TUYVLHMUEJTDNN-WVAUJHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15641409P | 2009-02-27 | 2009-02-27 | |
| US61/156,414 | 2009-02-27 | ||
| US25736709P | 2009-11-02 | 2009-11-02 | |
| US61/257,367 | 2009-11-02 | ||
| PCT/US2010/025611 WO2010099458A1 (en) | 2009-02-27 | 2010-02-26 | Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrosis and impaired liver function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011139180A true RU2011139180A (ru) | 2013-04-10 |
Family
ID=42111299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011139180/15A RU2011139180A (ru) | 2009-02-27 | 2010-02-26 | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции |
Country Status (22)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2906207T3 (es) | 2003-05-30 | 2022-04-13 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| NZ565059A (en) | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
| GEP20104956B (en) * | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| KR101848099B1 (ko) | 2009-09-21 | 2018-04-11 | 길리애드 사이언시즈, 인코포레이티드 | 1'-치환된 카바-뉴클레오사이드 유사체의 제조를 위한 방법 및 중간체 |
| KR20200052384A (ko) | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
| US20120027752A1 (en) | 2010-07-22 | 2012-02-02 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| WO2012062691A1 (en) * | 2010-11-09 | 2012-05-18 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for treating hcv infections |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| MX355102B (es) | 2012-01-11 | 2018-04-05 | Abbvie Ireland Unlimited Co | Procesos para hacer los inhibidores de la proteasa del hcv. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX2014014878A (es) * | 2012-06-12 | 2015-04-08 | Hoffmann La Roche | Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv). |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| PT2897611T (pt) * | 2012-09-18 | 2019-11-27 | Abbvie Inc | Métodos para tratamento da hepatite c |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| EP4667053A2 (en) | 2015-03-06 | 2025-12-24 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| BR122020020217B1 (pt) | 2015-09-16 | 2021-08-17 | Gilead Sciences, Inc | Uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por arenaviridae |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| SMT202200072T1 (it) | 2016-09-07 | 2022-03-21 | Atea Pharmaceuticals Inc | Nucleotidi purinici 2'-sostituiti-n6-sostituiti per il trattamento dei virus rna |
| CN106674224A (zh) * | 2016-12-20 | 2017-05-17 | 天津迈德新医药科技有限公司 | mPEG4‑阿巴卡韦及其制备方法和应用 |
| FI3577124T3 (fi) | 2017-02-01 | 2025-02-13 | Atea Pharmaceuticals Inc | Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| EP3618929B1 (en) | 2017-05-01 | 2022-12-07 | Gilead Sciences, Inc. | A crystalline form of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| ES3000461T3 (en) | 2017-07-11 | 2025-02-28 | Gilead Sciences Inc | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| EP4096678A1 (en) | 2020-01-27 | 2022-12-07 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| US11701372B2 (en) | 2020-04-06 | 2023-07-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs |
| PL4157272T3 (pl) | 2020-05-29 | 2025-10-20 | Gilead Sciences, Inc. | Remdesiwir do leczenia zakażeń wirusowych |
| TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
| DK4204421T3 (da) | 2020-08-27 | 2024-05-27 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til behandling af virale infektioner |
| AU2022291927A1 (en) | 2021-06-17 | 2024-01-04 | Atea Pharmaceuticals, Inc. | Advantageous anti-hcv combination therapy |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (196)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
| US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
| US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
| EP0206497B1 (en) | 1985-05-15 | 1994-07-20 | The Wellcome Foundation Limited | Therapeutic nucleosides and their preparation |
| US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
| US5149820A (en) | 1987-03-11 | 1992-09-22 | Norsk Hydro A.S. | Deuterated compounds |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5232928A (en) | 1989-07-25 | 1993-08-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tetrahydroisoquinoline amides |
| US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6693072B2 (en) | 1994-06-02 | 2004-02-17 | Aventis Pharmaceuticals Inc. | Elastase inhibitors |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US7157430B2 (en) | 1998-10-22 | 2007-01-02 | Idun Pharmaceuticals, Inc. | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| IL152022A0 (en) | 2000-04-03 | 2003-04-10 | Vertex Pharma | Compounds useful as protease inhibitors and pharmaceutical compositions containing the same |
| US6846802B2 (en) | 2000-04-05 | 2005-01-25 | Schering Corporation | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties |
| JP4748912B2 (ja) | 2000-04-19 | 2011-08-17 | シェーリング コーポレイション | アルキルおよびアリールアラニンｐ２部分を含むｃ型肝炎ウイルスに対する大員環ｎｓ３−セリンプロテアーゼ阻害剤 |
| CN102372764A (zh) | 2000-07-21 | 2012-03-14 | 先灵公司 | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| ES2263687T3 (es) | 2000-11-20 | 2006-12-16 | Bristol-Myers Squibb Company | Inhibidores tripeptidicos de la hepatitis c. |
| DE60229059D1 (de) | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
| DE10129832A1 (de) | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| ATE349463T1 (de) | 2001-07-11 | 2007-01-15 | Vertex Pharma | Verbrückte bizyklische serinproteaseinhibitoren |
| DE10162121A1 (de) | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2370400A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MXPA04009938A (es) | 2002-04-11 | 2004-12-13 | Vertex Pharma | Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv. |
| DE60315023T2 (de) | 2002-04-26 | 2008-04-03 | Gilead Sciences, Inc., Foster City | Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst |
| ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ATE503764T1 (de) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
| ES2315568T3 (es) | 2002-05-20 | 2009-04-01 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido. |
| JP3598381B2 (ja) | 2002-07-02 | 2004-12-08 | 独立行政法人物質・材料研究機構 | 一般式；ＢＮで示され、六方晶系５Ｈ型ないしは６Ｈ型多形構造を有し、紫外域で発光するｓｐ３結合型窒化ホウ素とその製造方法、及びこれを利用した機能性材料 |
| US20040138109A1 (en) | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
| PL199412B1 (pl) | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| RS20050741A (sr) | 2003-04-02 | 2007-06-04 | Boehringer Ingelheim International Gmbh., | Farmaceutske kompozicije za inhibitore virusne proteaze hepatitisa c |
| WO2004092203A2 (en) | 2003-04-10 | 2004-10-28 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic compounds |
| EP1613620A1 (en) | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| US7173004B2 (en) | 2003-04-16 | 2007-02-06 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus |
| WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| US20040229848A1 (en) | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
| ES2906207T3 (es) * | 2003-05-30 | 2022-04-13 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
| US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| US20050119189A1 (en) | 2003-09-18 | 2005-06-02 | Cottrell Kevin M. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| KR20060130027A (ko) | 2003-10-10 | 2006-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제 |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| RS20110578A3 (en) | 2003-10-14 | 2016-02-29 | F. Hoffmann-La Roche Ltd | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS |
| CN1894276B (zh) | 2003-10-27 | 2010-06-16 | 威特克斯医药股份有限公司 | Hcv ns3-ns4a蛋白酶抗药性突变体 |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2539575C (en) | 2003-11-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Method of removing transition metals, especially from metathesis reaction products |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2007513971A (ja) | 2003-12-11 | 2007-05-31 | シェーリング コーポレイション | Ｃ型肝炎ウイルスｎｓ３／ｎｓ４ａプロテアーゼの阻害剤 |
| DE602005025855D1 (de) | 2004-01-21 | 2011-02-24 | Boehringer Ingelheim Pharma | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
| PT1713823E (pt) | 2004-01-30 | 2010-02-02 | Medivir Ab | Inibidores da protease ns-3 da serina do hcv |
| EP1711515A2 (en) | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| RU2006134000A (ru) | 2004-02-27 | 2008-04-10 | Шеринг Корпорейшн (US) | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с |
| US7205330B2 (en) | 2004-02-27 | 2007-04-17 | Schering Corporation | Inhibitors of hepatitis C virus NS3 protease |
| KR20060124729A (ko) | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의신규한 화합물 |
| ATE438622T1 (de) | 2004-02-27 | 2009-08-15 | Schering Corp | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| DE602005019700D1 (de) | 2004-03-15 | 2010-04-15 | Boehringer Ingelheim Int | E, die sich für die behandlung von hepatitis-c-virusinfektionen eignen |
| JP2008502718A (ja) | 2004-05-20 | 2008-01-31 | シェーリング コーポレイション | Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての置換型プロリン |
| CA2568008C (en) | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
| US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102004033312A1 (de) | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
| CA2573207C (en) * | 2004-07-14 | 2013-04-16 | Novartis Ag | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) |
| CA2571984C (en) | 2004-07-16 | 2012-04-10 | Gilead Sciences, Inc. | Antiviral compounds |
| ES2366478T3 (es) | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
| US7550559B2 (en) | 2004-08-27 | 2009-06-23 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease |
| CA2578428A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
| WO2006096459A2 (en) | 2005-03-04 | 2006-09-14 | The Rockefeller University | Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof |
| KR101514953B1 (ko) | 2005-03-08 | 2015-04-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 매크로사이클릭 화합물의 제조방법 |
| US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| AU2006250068A1 (en) | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-IGG fusion |
| US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| US20060276405A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
| US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| NZ565059A (en) | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
| ATE524475T1 (de) | 2005-07-29 | 2011-09-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| GEP20104956B (en) | 2005-10-11 | 2010-04-12 | Array Biopharma Inc | Compounds for inhibiting hepatitis c viral replication and use thereof |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| KR101020440B1 (ko) | 2005-11-16 | 2011-03-08 | 에프. 호프만-라 로슈 아게 | 응고 인자 Ｘａ의 억제제로서의 피롤리딘 유도체 |
| CN101336247B (zh) * | 2005-12-09 | 2013-01-23 | 豪夫迈·罗氏有限公司 | 抗病毒核苷 |
| US7728148B2 (en) | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
| US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| US20090203008A1 (en) | 2006-06-08 | 2009-08-13 | Ludmerer Steven W | Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples |
| PE20080992A1 (es) | 2006-06-26 | 2008-08-06 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US8338593B2 (en) * | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| MX2009000486A (es) | 2006-07-13 | 2009-01-27 | Achillion Pharmaceuticals Inc | Peptidos de 4-amino-4-oxobutanoilo como inhibidores de replicacion viral. |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| CN101674844A (zh) | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂 |
| US20090035267A1 (en) | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7718612B2 (en) | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| US7662779B2 (en) | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| US20080038225A1 (en) | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US7687459B2 (en) | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US20090098085A1 (en) | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20090035268A1 (en) | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
| US20080107625A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010510192A (ja) | 2006-11-17 | 2010-04-02 | テイボテク・フアーマシユーチカルズ・リミテツド | Ｃ型肝炎ウイルスの大環状阻害剤 |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| JP2010518128A (ja) | 2007-02-16 | 2010-05-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ｎｓ３プロテアーゼのインヒビター |
| CN101679240A (zh) | 2007-03-23 | 2010-03-24 | 先灵公司 | Hcv ns3蛋白酶的p1-非可差向异构化酮酰胺抑制剂 |
| MX2009011370A (es) | 2007-04-24 | 2009-11-05 | Hoffmann La Roche | Proceso para el intermediario del inhibidor proteasa de hcv. |
| US7906513B2 (en) | 2007-04-26 | 2011-03-15 | Enanta Pharmaceuticals, Inc. | Hydrazide-containing hepatitis C serine protease inhibitors |
| US20090123423A1 (en) | 2007-04-26 | 2009-05-14 | Yonghua Gai | Hydroxyamic analogs as hepatitis c virus serine protease inhibitor |
| US20080274082A1 (en) | 2007-04-26 | 2008-11-06 | Yonghua Gai | Oximyl hydroxyamic analogs as hepatitis c virus protease inhibitor |
| US20080279821A1 (en) | 2007-04-26 | 2008-11-13 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors |
| US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
| US20080267917A1 (en) | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| US7910587B2 (en) | 2007-04-26 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl dipeptide hepatitis C virus inhibitors |
| US20080317712A1 (en) | 2007-04-26 | 2008-12-25 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl tripeptide hepatitis c serine protease inhibitors |
| WO2008134395A1 (en) | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
| EP2160392A2 (en) | 2007-05-03 | 2010-03-10 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US7932277B2 (en) | 2007-05-10 | 2011-04-26 | Intermune, Inc. | Peptide inhibitors of hepatitis C virus replication |
| JP2010528013A (ja) * | 2007-05-21 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン |
| US20090005387A1 (en) | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20090053175A1 (en) | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| US20090060874A1 (en) | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
| CA2700383A1 (en) | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Urea-containing peptides as inhibitors of viral replication |
| US20090082366A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| WO2009055335A2 (en) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8426360B2 (en) | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
| US8361958B2 (en) | 2007-12-05 | 2013-01-29 | Enanta Pharmaceuticals, Inc. | Oximyl HCV serine protease inhibitors |
| WO2009085978A1 (en) | 2007-12-20 | 2009-07-09 | Enanta Pharceuticals, Inc. | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors |
| MX2010006659A (es) | 2007-12-21 | 2010-07-05 | Hoffmann La Roche | Proceso para la preparacion de un macrociclo. |
| JP5574982B2 (ja) | 2008-02-04 | 2014-08-20 | イデニク プハルマセウティカルス，インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
| CN101969973B (zh) | 2008-02-07 | 2015-07-22 | 维罗贝股份有限公司 | 组织蛋白酶b抑制剂 |
| WO2009124853A1 (en) | 2008-04-11 | 2009-10-15 | F. Hoffmann-La Roche Ag | New ruthenium complexes as catalysts for metathesis reactions |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| WO2009134987A1 (en) | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| US20090285773A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20090285774A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN101580535B (zh) | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| CA2729168A1 (en) | 2008-07-02 | 2010-02-04 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010015545A1 (en) | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| JP5539363B2 (ja) | 2008-09-17 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ |
| US8603737B2 (en) | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2012505897A (ja) | 2008-10-15 | 2012-03-08 | インターミューン・インコーポレーテッド | 治療用抗ウイルス性ペプチド |
| WO2010059937A1 (en) | 2008-11-20 | 2010-05-27 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus |
| NZ592705A (en) | 2008-12-10 | 2013-02-22 | Achillion Pharmaceuticals Inc | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2011006631A (es) | 2008-12-19 | 2011-09-06 | Gilead Sciences Inc | Inhibidores de proteasa ns3 del virus hcv. |
| EP2367813A1 (en) | 2008-12-22 | 2011-09-28 | Gilead Sciences, Inc. | Antiviral compounds |
| US20100196321A1 (en) | 2009-01-30 | 2010-08-05 | Glaxosmithkline Llc | Compounds |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| TR201809600T4 (tr) | 2009-04-25 | 2018-07-23 | Hoffmann La Roche | Farmakokinetiği geliştirmek için yöntemler. |
| AR077139A1 (es) | 2009-06-23 | 2011-08-03 | Gilead Sciences Inc | Composiciones farmaceuticas utiles para tratar el vch |
| TW201111381A (en) | 2009-06-23 | 2011-04-01 | Gilead Sciences Inc | Pharmaceutical combinations useful for treating HCV |
| US20100324059A1 (en) | 2009-06-23 | 2010-12-23 | Gilead Sciences, Inc. | Pharmaceutical compositions useful for treating hcv |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| BR112012006835A2 (pt) | 2009-09-28 | 2016-06-07 | Hoffmann La Roche | inibidores macrocíclicos da replicação do vírus de hepatite c |
-
2010
- 2010-02-23 AR ARP100100517A patent/AR075584A1/es unknown
- 2010-02-26 KR KR1020117021515A patent/KR20110135941A/ko not_active Ceased
- 2010-02-26 NZ NZ594524A patent/NZ594524A/xx not_active IP Right Cessation
- 2010-02-26 BR BRPI1009338A patent/BRPI1009338A2/pt not_active IP Right Cessation
- 2010-02-26 JP JP2011552194A patent/JP2012519181A/ja active Pending
- 2010-02-26 TW TW99105744A patent/TWI473810B/zh not_active IP Right Cessation
- 2010-02-26 US US13/203,334 patent/US20120128628A1/en not_active Abandoned
- 2010-02-26 MA MA34087A patent/MA33236B1/fr unknown
- 2010-02-26 US US12/713,497 patent/US8735345B2/en not_active Expired - Fee Related
- 2010-02-26 RU RU2011139180/15A patent/RU2011139180A/ru unknown
- 2010-02-26 EP EP10706121A patent/EP2400966A1/en not_active Withdrawn
- 2010-02-26 CN CN2010800099017A patent/CN102361641A/zh active Pending
- 2010-02-26 AU AU2010217818A patent/AU2010217818A1/en not_active Abandoned
- 2010-02-26 SG SG2011059904A patent/SG173774A1/en unknown
- 2010-02-26 CA CA2751220A patent/CA2751220A1/en not_active Abandoned
- 2010-02-26 PE PE2011001548A patent/PE20120777A1/es not_active Application Discontinuation
- 2010-02-26 MX MX2011008980A patent/MX2011008980A/es active IP Right Grant
- 2010-02-26 WO PCT/US2010/025611 patent/WO2010099458A1/en not_active Ceased
-
2011
- 2011-08-21 IL IL214760A patent/IL214760A0/en unknown
- 2011-08-23 CR CR20110453A patent/CR20110453A/es not_active Application Discontinuation
- 2011-08-25 CO CO11108893A patent/CO6410304A2/es not_active Application Discontinuation
- 2011-08-26 CL CL2011002082A patent/CL2011002082A1/es unknown
- 2011-08-26 EC EC2011011292A patent/ECSP11011292A/es unknown
-
2015
- 2015-03-03 JP JP2015041648A patent/JP2015098501A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MA33236B1 (fr) | 2012-05-02 |
| CR20110453A (es) | 2011-12-08 |
| JP2015098501A (ja) | 2015-05-28 |
| US8735345B2 (en) | 2014-05-27 |
| SG173774A1 (en) | 2011-09-29 |
| CL2011002082A1 (es) | 2012-04-13 |
| TW201035099A (en) | 2010-10-01 |
| WO2010099458A1 (en) | 2010-09-02 |
| AR075584A1 (es) | 2011-04-20 |
| IL214760A0 (en) | 2011-11-30 |
| US20120128628A1 (en) | 2012-05-24 |
| CN102361641A (zh) | 2012-02-22 |
| NZ594524A (en) | 2013-09-27 |
| EP2400966A1 (en) | 2012-01-04 |
| CA2751220A1 (en) | 2010-09-02 |
| KR20110135941A (ko) | 2011-12-20 |
| BRPI1009338A2 (pt) | 2016-11-01 |
| CO6410304A2 (es) | 2012-03-30 |
| TWI473810B (zh) | 2015-02-21 |
| JP2012519181A (ja) | 2012-08-23 |
| AU2010217818A1 (en) | 2011-08-18 |
| PE20120777A1 (es) | 2012-06-27 |
| ECSP11011292A (es) | 2011-12-30 |
| MX2011008980A (es) | 2011-11-18 |
| US20100221217A1 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| JP2012519181A5 (cg-RX-API-DMAC7.html) | ||
| HRP20130098T1 (hr) | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a | |
| US8399484B2 (en) | Combination therapy for treating HCV infection | |
| HUP0003384A2 (hu) | Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék | |
| ZA200102917B (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection. | |
| US20050112093A1 (en) | Combination therapy for HCV infection | |
| JP2011519364A5 (cg-RX-API-DMAC7.html) | ||
| JP2008530124A (ja) | フラビウイルス感染症を処置または予防するための組成物および方法 | |
| EP3137078B1 (en) | Treatment of hepatitis delta virus infection | |
| US20220023287A1 (en) | Treatment of hepatitis delta virus infection | |
| HK1048951A1 (zh) | 与PEG-IFN-α结合的霉酚酸酯MOFETIL | |
| US20150139950A1 (en) | Alisporivir to treat hepatitis c virus infection | |
| ES2968931T3 (es) | Efecto sinérgico de eyp001 e ifn-alfa pegilado para el tratamiento de la infección por hbv | |
| RU2009128978A (ru) | Соединения и фармацевтические композиции для лечения вирусных инфекций | |
| Waters et al. | New therapeutic options for hepatitis C | |
| Khokhar et al. | Future therapies for hepatitis C | |
| WO2015166071A1 (en) | Combination therapy for treating hcv infection | |
| JP2004155777A (ja) | Ｃ型慢性肝炎治療剤 | |
| WO2006010256A1 (en) | Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases | |
| EA046230B1 (ru) | Синергическое действие eyp001 и ifn при лечении инфекции hbv | |
| US20150104415A1 (en) | Treatments of Hepatitis C virus infection | |
| CA2614639A1 (en) | Pharmaceutical composition for treatment of blood clotting disorder | |
| Davies et al. | Isatoribine | |
| Pockros | Medical Writers’ Circle |